Myasthenia Gravis

Myasthenia Gravis

Feb 04, 2019


Myasthenia gravis (MG) is an autoimmune syndrome caused by the failure of neuromuscular transmission, which results from the binding of autoantibodies to proteins involved in signaling at the neuromuscular junction (NMJ). These proteins include the nicotinic Acetyl Cholinesterase (AChR) or, less frequently, a muscle-specific tyrosine kinase (MuSK). 

To get a free sample report, click the link: https://www.delveinsight.com/report-store/myasthenia-gravis-market-insight-epidemiology-and-market-forecast

Downloads

Article in PDF

Recent Articles
  1. Late-Breaking Science at AAN 2025: Shaping the Future of Neurology
  2. Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma...
  3. Business Cocktail
  4. Myasthenia Gravis Awareness Month
  5. Top 12 Most Expensive Drugs in the US Healthcare Market
aan-2025-highlights
Articles

Late-Breaking Science at AAN 2025: Shaping the Future of Neurology

pharma-news-for-eisai-vanda-cartesian
Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Approves LEQEMBI IV Dosing for Early Alzheimer’s; Vanda Accepts FDA Hearing on Tradipitant for Gastroparesis; Cartesian Gains FDA Protocol Approval for Myasthenia Gravis Trial; Zai Lab Secures FDA Orphan Status for DLL3 ADC in SCLC; Dyne Receives FDA Fast Track for DYNE-101 in Myotonic Dystrophy

fcrn-inhibitors-in-20-indications
Articles

FcRn Inhibitors Being The Fastest Growing Class, Plans To Get Explored In 20+ Indications

myasthenia gravis
myasthenia gravis (MG)
Myasthenia Gravis market
Myasthenia Gravis market forecast
Myasthenia Gravis market trends
loader
loader